RATIO-VALPROIC CAPSULE (ENTERIC-COATED)
Země: Kanada
Jazyk: angličtina
Zdroj: Health Canada
Charakteristika produktu
(SPC)
12-10-2016
Některé dokumenty pro tento produkt momentálně nejsou k dispozici, můžete poslat požadavek našemu zákaznickému servisu a my vás upozorníme, jakmile je dokážeme získat.
Poslat žádost.
Poslat žádost.
Aktivní složka:
VALPROIC ACID
Dostupné s:
TEVA CANADA LIMITED
ATC kód:
N03AG01
INN (Mezinárodní Name):
VALPROIC ACID
Dávkování:
500MG
Léková forma:
CAPSULE (ENTERIC-COATED)
Složení:
VALPROIC ACID 500MG
Podání:
ORAL
Jednotky v balení:
100/500
Druh předpisu:
Prescription
Terapeutické oblasti:
MISCELLANEOUS ANTICONVULSANTS
Přehled produktů:
Active ingredient group (AIG) number: 0112996003; AHFS:
Stav Autorizace:
MARKETED
Datum autorizace:
2007-07-13
Charakteristika produktu
PRODUCT MONOGRAPH
PR
RATIO-VALPROIC
(VALPROIC ACID)
Capsules
Capsules (250 mg and 500 mg)
USP
Antiepileptic
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada M1B 2K9
www.tevacanada.com
Date of Preparation :
July 24, 2013
Submission Control No: 166248
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................. 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
16
DRUG INTERACTIONS
.........................................................................................................
19
DOSAGE AND ADMINISTRATION
.....................................................................................
26
OVERDOSAGE
.......................................................................................................................
28
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 29
STORAGE AND STABILITY
.................................................................................................
32
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 32
PART II: SCIENTIFIC INFORMATION
....................................................................................
33
PHARMACEUTICAL INFORMATION
.................................................................................
33
CLINICAL TRIALS
.................................................................................................................
Přečtěte si celý dokument
